Development of pro-angiogenic engineered transcription factors for the treatment of cardiovascular disease

ISSN： 1354-3784

Source： Expert Opinion on Investigational Drugs, Vol.13, Iss.7, 2004-07, pp. : 829-839

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Pro-angiogenic Molecules for Therapeutic Angiogenesis

Current Medicinal Chemistry, Vol. 24, Iss. 31, 2017-10 ,pp. : 3413-3432

Bentham Science Publishers

Access to resources Recommend Favorite

Engineered transcription factors induce angiogenesis

Inpharma, Vol. 1, Iss. 1374, 2003-01 ,pp. : 12-12

Adis International

Access to resources Recommend Favorite

Regulation of Angiogenesis and Angiogenic Factors by Cardiovascular Medications

Current Pharmaceutical Design, Vol. 13, Iss. 20, 2007-07 ,pp. : 2113-2117

Bentham Science Publishers

Access to resources Recommend Favorite

Nuclear Receptors and Transcription Factors in the Development of Fatty Liver Disease

Current Drug Metabolism, Vol. 13, Iss. 10, 2012-12 ,pp. : 1422-1435

Bentham Science Publishers

Access to resources Recommend Favorite

Trastuzumab modulates the effects of both pro- and anti-angiogenic factors

Inpharma, Vol. 1, Iss. 1333, 2002-01 ,pp. : 19-19

Adis International

Access to resources Recommend Favorite